Evidence from preclinical and clinical studies suggests that combination treatment with anti-HER2 therapies and PI3K pathway inhibitors may have potential efficacy in HER2+ breast cancers with PIK3CA mutations18–20. The gene discussed is PIK3CA; the disease is breast carcinoma.